A comprehensive lattice study of SU(3) glueballs

We present a study of the $SU(3)$ glueball spectrum for all $J^{PC}$ values at lattice spacings down to $a^{-1}=3.73 (6)$ GeV ($\beta=6.4$) using lattices of size up to $32^4$. We extend previous studies and show that the continuum limit has effectively been reached. The number of clearly identified $J^{PC}$ states has been substantially increased. There are no clear signals for spin-exotic glueballs below 3 GeV. A comparison with current experimental glueball candidates is made.Comment: 10 pages including 2 PS figures, Liverpool Preprint: LTH 303, Wuppertal Preprint: WUB 93-1

Gauge-ball spectrum of the four-dimensional pure U(1) gauge theory

We investigate the continuum limit of the gauge-ball spectrum in the four-dimensional pure U(1) lattice gauge theory. In the confinement phase we identify various states scaling with the correlation length exponent $\nu \simeq 0.35$. The square root of the string tension also scales with this exponent, which agrees with the non-Gaussian fixed point exponent recently found in the finite size studies of this theory. Possible scenarios for constructing a non-Gaussian continuum theory with the observed gauge-ball spectrum are discussed. The $0^{++}$ state, however, scales with a Gaussian value $\nu \simeq 0.5$. This suggests the existence of a second, Gaussian continuum limit in the confinement phase and also the presence of a light or possibly massless scalar in the non-Gaussian continuum theory. In the Coulomb phase we find evidence for a few gauge-balls, being resonances in multi-photon channels; they seem to approach the continuum limit with as yet unknown critical exponents. The maximal value of the renormalized coupling in this phase is determined and its universality confirmed.Comment: 46 pages, 12 figure

Mouse Chromosome 11

Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/46996/1/335_2004_Article_BF00648429.pd

Dimethyl fumarate in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

Dimethyl fumarate (DMF) inhibits inflammasome-mediated inflammation and has been proposed as a treatment for patients hospitalised with COVID-19. This randomised, controlled, open-label platform trial (Randomised Evaluation of COVID-19 Therapy [RECOVERY]), is assessing multiple treatments in patients hospitalised for COVID-19 (NCT04381936, ISRCTN50189673). In this assessment of DMF performed at 27 UK hospitals, adults were randomly allocated (1:1) to either usual standard of care alone or usual standard of care plus DMF. The primary outcome was clinical status on day 5 measured on a seven-point ordinal scale. Secondary outcomes were time to sustained improvement in clinical status, time to discharge, day 5 peripheral blood oxygenation, day 5 C-reactive protein, and improvement in day 10 clinical status. Between 2 March 2021 and 18 November 2021, 713 patients were enroled in the DMF evaluation, of whom 356 were randomly allocated to receive usual care plus DMF, and 357 to usual care alone. 95% of patients received corticosteroids as part of routine care. There was no evidence of a beneficial effect of DMF on clinical status at day 5 (common odds ratio of unfavourable outcome 1.12; 95% CI 0.86-1.47; p = 0.40). There was no significant effect of DMF on any secondary outcome

The functional and evolutionary significance of Schreckstoff in natural communities of fish

SIGLEAvailable from British Library Document Supply Centre-DSC:D191471 / BLDSC - British Library Document Supply CentreGBUnited Kingdo